In a retrospective review of 418 tunneled pleural catheters placed over 2 years, 91% of patients did not require any other drainage procedure. Spontaneous pleurodesis occurred in one-quarter, in whom the catheter was taken out at a median 44 days. More patients with catheters placed in the operating room achieved pleurodesis (36%). Complication rate overall [… read more]
Survival varies widely among people with N1 non-small cell lung cancer. Examining SEER data on 1,682 patients age > 65, who had a median 8 lymph nodes resected between 1992 and 2005, Wisnivesky et al observe that the ratio of positive-to-negative sampled lymph nodes independently predicted survival. Having more than 50% positive LNs foretold a median survival [… read more]
Establishing mediastinal spread of non-small cell lung cancer (N2-3 disease) precludes surgery and worsens prognosis; whether PET-CT imaging can improve overall accuracy or safely prevent mediastinoscopies is still unknown. Fischer et al re-heat the data from their 2009 NEJM randomized trial in Denmark, with EUS-FNA and mediastinoscopy on 189 NSCLC patients, in which they concluded that the [… read more]
Ashraf et al selected people with lung nodules from the Danish Lung Cancer Screening Trial, referring them for PET. Having a suspicious PET scan, or a volume-doubling time (VDT) of < 1 year, each separately had a sensitivity of 71% and a specificity of 91% for lung cancer. Combining PET data with VDT improved sensitivity [… read more]
A retrospective look at 447 patients with stage I non-small cell lung cancer by Inoue et al suggests yes, but without affecting survival. When cancer recurred in those initially diagnosed by CT-guided needle biopsy, pleural dissemination was more likely (8 of 13 recurrences). However, 5-year disease free survival was 89% in the CT-biopsy group and [… read more]
Almost half of 115 Philadelphia veterans diagnosed with lung cancer had recently quit smoking, at a median 2.7 years prior to their lung cancer diagnosis; only 11% recalled having any symptoms of lung cancer at the time of quitting. J Thorac Oncol 2011;6:517-524.
In 186 patients who underwent transbronchial needle aspiration at an experienced center, followed by endoscopic biopsy or surgery as a gold standard, the positive predictive value of FNA cytology for adenocarcinoma was 92% and for squamous cell carcinoma, 82%. J Thorac Oncol 2011;6:489-493.
Treating NSCLC with tyrosine kinase / EGFR inhibitors erlotinib & gefitinib: Cataldo VD, NEJM 2011;364:947-955. Non small cell lung cancer chemotherapy treatment review.
Cao et al report experience with 186 patients with resected bronchopulmonary carcinoid in Australia; median survival was 20 years. Those older than 60 at presentation and/or with higher-grade/atypical tumor histopathology had worse survival. Ann Thorac Surg 2011;91:339-343.
The IASLC, ATS, and ERS got together to better incorporate clinical logic into classification of NSCLC. No more bronchioloalveolar carcinoma (they propose adenocarcinoma in situ or invasive mucinous adenocarcinoma, depending on its size). Large cell carcinoma with neuroendocrine features gets separated out of NSCLC entirely, so it can be treated as small cell. And so [… read more]